EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort

Claire Moore iD, Andreas Halman iD, Tayla Stenta iD, Dhrita Khatri iD, Elizabeth Williams iD, Roxanne Dyas iD, Julian Stolper iD, David A Elliott iD, Rachel Conyers iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Claire Moore und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Neoplasms, Pharmacogenomic Testing, Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Melbourne University Strategic Research Training Program (RTP) Scholarship, The Kids' Cancer Project, The Royal Children's Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomics remains underutilized in pediatric oncology, despite the existence of evidence‐based guidelines. Implementation of pharmacogenomics‐informed prescribing could improve medication safety and efficacy in pediatric oncology patients, who are at high risk of adverse drug reactions. This study examines the prevalence of high‐risk pharmacogenomic phenotypes and the prescription of relevant medications in a diverse Australian pediatric oncology cohort, highlighting the potential impact of pharmacogenomic testing in this unique population. Whole genome sequencing data from 180 patients were analyzed to assess 14 genes with evidence‐based pharmacogenomic guidelines relevant to pediatric oncology. Over 90% of patients had at least one high‐risk phenotype, with 20% presenting four or more. Ondansetron, mercaptopurine, omeprazole, pantoprazole, and voriconazole were commonly prescribed medications that have pharmacogenomic prescribing recommendations, with the latter three showing the highest actionability rates. High‐risk phenotypes were most frequently observed for CYP2C19 and CYP2D6 , with 30% of patients having a high‐risk phenotype for both genes. This study underscores the potential utility of pharmacogenomics in pediatric oncology patients across a range of pharmacogenes and commonly prescribed medications. The findings support advocacy for implementing broad, pre‐emptive pharmacogenomic testing in oncology patients to improve treatment safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPharmacogenomic TestingPharmacogeneticsDrug-Related Side Effects and Adverse ReactionsAntineoplastic AgentsHumansChildAustraliaMalePhenotypeFemaleChild, PreschoolAdolescentInfantCytochrome P-450 CYP2C19Whole Genome SequencingCohort StudiesCytochrome P-450 CYP2D6

Stichwörter der Autor:innen

medical oncologypediatricspharmacogeneticspharmacogenomicsprecision medicine

Substanzen

Cytochrome P-450 CYP2C19CYP2C19 protein, humanCytochrome P-450 CYP2D6Antineoplastic Agents

Autor:innen und Institutionen

  • Cancer Therapies, Stem Cell Medicine, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
  • Children's Cancer Centre, The Royal Children's Hospital, Parkville, Victoria, Australia.
  • Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
  • The Novo Nordisk Foundation Centre for Stem Cell Medicine, ReNEW, Melbourne Node, Parkville, Victoria, Australia.
  • Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Claire Moore, Andreas Halman, Tayla Stenta, Dhrita Khatri, Elizabeth Williams, Roxanne Dyas, Julian Stolper, David A Elliott, Rachel Conyers

Förderung

  • Melbourne University Strategic Research Training Program (RTP) Scholarship
  • The Kids' Cancer Project
  • The Royal Children's Hospital Foundation
  • 2020 Medical Research Future Fund - Emerging Priorities and Consumer Driven Research Initiative - Paediatric Cancer
  • 2023 Medical Research Future Fund - Genomics Health Future Mission
  • Royal Children's Hospital Foundation

Zitieren

APA

Moore, C., Halman, A., Stenta, T., Khatri, D., Williams, E., Dyas, R., Stolper, J., Elliott, D. A., & Conyers, R. (2025). Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. Clinical and Translational Science. https://doi.org/10.1111/cts.70246

Vancouver

Moore C, Halman A, Stenta T, Khatri D, Williams E, Dyas R, et al. Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort. Clinical and Translational Science. 2025. doi:10.1111/cts.70246

BibTeX
@article{Moore2025,
  author = {Moore, Claire and Halman, Andreas and Stenta, Tayla and Khatri, Dhrita and Williams, Elizabeth and Dyas, Roxanne and Stolper, Julian and Elliott, David A and Conyers, Rachel},
  title = {Frequency and Implications of High‐Risk Pharmacogenomic Phenotypes Identified in a Diverse Australian Pediatric Oncology Cohort},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70246}
}
Kostenlos starten →